This site might not work as expected.
You're using an old browser that isn't supported by this site. Please upgrade or download one of these free and excellent browsers:

Dr. John Byrd Joins Oncology Times as Clinical Advisory Editor

Distinguished clinician-scientist John Byrd will provide expert commentary on important developments in hematological oncology

​The editors and publisher of  Oncology Times, the independent source for hematology/oncology news for the cancer care team, are pleased to announce the appointment of John C. Byrd, MD, as Clinical Advisory Editor. Oncology Times is published by  Lippincott Williams & Wilkins, a part of  Wolters Kluwer Health.

Dr. Byrd is D. Warren Brown Chair of Leukemia Research and Professor of Medicine, Medicinal Chemistry and Veterinary Biosciences and Director of the Division of Hematology at The Ohio State University, Columbus.

"It's a great pleasure to have a distinguished clinician-scientist like John Byrd join our team to provide expert commentary on important developments in hematological oncology," said Oncology Times Editorial Board Chair Robert C. Young, MD.

Dr. Byrd provides an insightful view from the leading edge of translational oncology research, informed by his perspectives as a clinician and educator.  His research work has led to the identification of several therapeutic agents active in chronic lymphocytic leukemia and related leukemias and lymphomas, including ibrutinib, idelalisib, dinaciclib, flavopiridol, otlertuzumab, MOR208, and rituximab.

In addition to his busy research schedule, Dr. Byrd maintains an active role in providing clinical care for patients.

He is a member of the American Society of Hematology, American Society of Clinical Oncology, the Alliance for Clinical Trials in Oncology (formerly CALGB), and American Society of Clinical Investigation. 

Dr. Byrd's publication experience includes serving as an Associate Editor for Blood and on the editorial boards of several other journals.  He has authored or co-authored more than 330 peer-reviewed publications and over 20 book chapters related to leukemia.

Through his contributions as Clinical Advisory Editor, Dr. Byrd will help to ensure that Oncology Times continues to support cancer care team members in fulfilling their most important role—providing excellent patient care.  Oncology Times Editor Serena Stockwell added, "We are delighted to have Dr. Byrd as part of our editorial team, and to have the benefit of his expertise, advice, and perspective."

About Oncology Times
Oncology Times, the independent source for hematology/oncology news for the cancer care team, reports on breaking clinical news as well as the professional, political, reimbursement, and practice-management issues that affect those treating cancer patients. Published for 36 years, OT appears twice a month in print—mailed to approximately 41,000 readers—and on the iPad, with daily updates online. The award-winning publication features targeted news for today's busy cancer care professionals along with provocative editorials and enlightening analysis and commentary.

About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health's market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include  Health Language ®Lexicomp ®Lippincott Williams & WilkinsMedicom®Medi-Span ®MedknowOvid ®Pharmacy OneSource®ProVation ® Medical and  UpToDate ®.

Wolters Kluwer Health is part of  Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Follow our official Twitter handle:  @WKHealth.